Cullinan Oncology (CGEM)

• Market cap: $830M
• 1 day: -6.38%
• 5 days: -17.57%
• 1 month: -9.57%
• 3 months: -13.4%
• 6 months: 27.57%
• Year to date: 33.5%
• 1 year: 54.58%
• 5 years: -60.1%
• 10 years: -54.83%
• Sector: Healthcare
• Industry: Biotechnology

About: Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Employees: 109